Clinical Trial

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-24; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT07047183
Lead Sponsor Yehui Tan
Conditions Myelodysplastic Neoplasms, Transplantation
Enrollment 46 participants
Start Date 2025-07-01
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-08